In the losartan intervention for endpoint reduction in hypertension life study in hypertensive patients with left ventricular hypertrophy lvh, the group of. The end point findings from the life study are of interest in particular, a 25% reduction in stroke rate with losartan compared to the atenolol group. The primary efficacy measure was the time to the first event of the composite. In the losartan intervention for endpoint reduction in hypertension life study, black patients with hypertension and left. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study life. The purpose of this study is to determine if losartan can reduce fibrosis in lymphoid tissues, calm an overactive immune system, improve immune system recovery, and decrease the size of the latent hiv reservoir in the body. Capitals indicate lifethreatening, underlines indicate most frequent. Losartan also significantly decreased the degree of proteinuria p losartan intervention for endpoint reduction in hypertension life study demonstrated that losartan based therapy reduced cardiovascular end points significantly better than atenololbased therapy for a similar reduction in blood pressure bp in patients with hypertension and left ventricular hypertrophy lvh. The renaal reduction of endpoints in niddm with the angiotensin ii antagonist losartan study is a multinational, doubleblind, randomized, placebo controlled trial which was recently published.
The losartan intervention for endpoint life reduction in hypertension study is a doubleblind, prospective, parallel group study designed to compare the effects of losartan with those of the b. Oct 25, 2003 lars lindholm and colleagues aug 23, p 6191 suggest that losartan is better than atenolol in reducing sudden cardiac death in diabetic hypertensives with leftventricular hypertrophy. Effect of losartan on sudden cardiac death in people with diabetes. Pdf pilot study of losartan for pulmonary hypertension. Listing a study does not mean it has been evaluated by the u. A detailed description of study design has been published elsewhere. Jun 20, 2006 losartan intervention for endpoint reduction in hypertension life study 09543 the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. More correct, would be to conclude that the life study implies that patients on a combination antihypertensive therapy, including losartan. The losartan intervention for endpoint reduction in hypertension study life is the only completed hypertension trial of an arb to assess cardiovascular outcomes. Losartan intervention for endpoint reduction life in.
Costeffectiveness of losartan versus atenolol in treating. Based on the losartan intervention for endpoint reduction in hypertension life study, losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. In a singledose study in normal volunteers, losartan had no effects on glomerular filtration rate, renal plasma. The losartan intervention for endpoint reduction life trial. Economic study endpoint the intended endpoint of this cost. The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 mg and do not change over time. The findings from one such trial, the losartan intervention for endpoint reduction in hypertension life study, were recently published and offer important insights into. Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. Effect of losartan on sudden cardiac death in people with. Patients with myocardial infarction or stroke within six months prior to randomization were excluded. Pdf a recent study of two widely used angiotensin receptor blockers reported a.
Beyond blood pressure reduction in the treatment of arterial. The study demonstrated that in type ii diabetic patients already receiving conventional antihypertensive therapy, the use of the angiotensiniireceptor antagonist losartan significantly decreased the risk of esrd 19. Evaluation of the losartan in hemodialysis elhe study. This conclusion is based on an analysis of the patients with diabetes enrolled in the losartan intervention for endpoint reduction in hypertension life study. As described previously, the losartan intervention for endpoint reduction life study was designed in the early 1990s when 1 reduction of cardiovascular. Dailymed losartan potassium and hydrochlorothiazide tablet.
Angiotensin converting enzyme inhibitors aceis have been shown to be effective in the treatment of dialysis patients with high blood pressure, however, they also have been associated with anaphylactoid reactions at the start of dialysis, when they have been used concomitantly with an69 membranes. Pharmacokinetics general losartan potassium losartan is an orally active agent that undergoes substantial firstpass metabolism by cytochrome p450 enzymes. Therapy with losartan compared to irbesartan was performed in a chinese sample of hypertensive patients with elevated serum uric acid sua levels. The life study was a multinational, doubleblind study comparing losartan potassium and atenolol in 9193 hypertensive patients with ecgdocumented left ventricular hypertrophy. Cardiovascular morbidity and mortality in the losartan intervention. Losartan more effective than atenolol in hypertension with.
Mar 30, 2006 the effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The losartan intervention for endpoint reduction life in hypertension study. The effect of losartan compared with atenolol on the. This finding could not be explained on any imbalances between the treatment groups or on the basis of differences in the populations, other than race. Losartan fda prescribing information, side effects and uses. Losartan vs atenolol in htn and lvhgreat reduction in cardiovascular morbidity and death than. Nov 10, 2005 therapy with losartan compared to irbesartan was performed in a chinese sample of hypertensive patients with elevated serum uric acid sua levels. In the life study, losartanbased therapy was associated with a lower. Sep 17, 2012 in the large, well designed life losartan intervention for endpoint reduction in hypertension study in patients with hypertension and lvh, losartan was more effective than atenolol in reducing the composite primary endpoint of cardiovascular cv mortality, stroke or myocardial infarction mi. Treatment with losartan in the life study resulted in a greater reduction in albuminuria compared with atenolol for the same reduction in blood pressure. Approximately onefifth of the superiority of losartan versus atenolol on the primary composite end point in the life study was due to its effect on albuminuria. Review of the molecular pharmacology of losartan and its.
Download fulltext pdf download fulltext pdf pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease article pdf available in respiratory research 61. The primary hypothesis of the life study was that selective angiotensinii type 1receptor antagonism with losartan would be more effective than. The terminal half life of losartan is about 2 hours and of the metabolite is about 69 hours. The effects of losartan compared to atenolol on stroke in. Effects of losartan on cardiovascular morbidity and mortality. Pdf fixed combination of losartan and hydrochlorothiazide and. Effects of losartan and irbesartan on serum uric acid in. Rank is a value from 0 to indicating how closely a match scored or ranked against the original search string. In the analysis of the subgroup of 1,195 patients with hypertension and diabetes included in the life study, losartan had a special prognostic benefit. The total number of occurrences of the original search wordsphrases in a portion of a book. Effects of losartan or atenolol in hypertensive patients.
We analysed the effect of aspirin in 9,193 hypertensive patients with left ventricular hypertrophy receiving either the betablocker atenolol or losartan in the life study. Study of the efficacy of losartan on aortic dilatation in patients with marfan syndrome official title icmje multicenter, randomised, double blind study of the efficacy of losartan on aortic dilatation in patients with marfan syndrome brief summary the purpose of this study is to evaluate if losartan limits aortic dilatation in patients with. The mechanism of the antihypertensive effect of thiazides is unknown. The life study assigned 9,193 patients with hypertension and left ventricular hypertrophy lvh to losartan or atenololbased therapy for a mean of. Feb 12, 2020 the life study was a multinational, doubleblind study comparing losartan potassium and atenolol in 9193 hypertensive patients with ecgdocumented left ventricular hypertrophy. Cozaar losartan potassium dose, indications, adverse. Pdf pilot study of losartan for pulmonary hypertension in.
For a list of investigators in the life study, see the appendix. The losartan intervention for endpoint reduction life in hypertension study is a doubleblind, prospective, parallel group study designed to compare the effects of losartan with those of the betablocker atenolol on the reduction of cardiovascular morbidity and mortality in approximately 8,300 hypertensive patients initial sitting diastolic. In the life study, black patients treated with atenolol were at a lower risk of experiencing cardiovascular events compared with black patients receiving losartan. Download fulltext pdf association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy.
Effects of losartan in women with hypertension and left. Does albuminuria predict cardiovascular outcomes on treatment. Pdf a fixeddose combination of losartanhydrochlorothiazide hctz. To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the swiss healthcare system. The losartan intervention for endpoint reduction life 2 study was designed in the early 1990s with consideration of several factors. Pdf healthcare costs of losartan and candesartan in the primary. Effects of losartan on cardiovascular morbidity and mortality in. Apr 06, 2020 the findings from one such trial, the losartan intervention for endpoint reduction in hypertension life study, were recently published and offer important insights into the workings of this drug. Aug 05, 2003 in hypertensive patients without clinically evident vascular disease, losartan was more effective than atenolol in preventing cardiovascular morbidity and death, predominantly stroke, independent of blood pressure reduction.
In a pilot study for life, almost 25% of treated patients with hypertension aged 5580 years showed signs of lvh by our ecg criteria. The losartan intervention for endpoint reduction life in. Losartan for cardiovascular disease in patients with and without. Losartan intervention for endpoint reduction in hypertension. The effect of losartan versus atenolol on cardiovascular morbidity. John cruickshank notes that the results of the life study should be generalised with care to a younger patient population and we agree, but we. Losartan for the treatment of hypertension and left. Nieminen, per omvik, suzanne oparil, hans wedel for the life study group, the losartan intervention for endpoint reduction life in hypertension study. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. Cardiovascular morbidity and mortality in the losartan. Pdf association of left bundle branch block with left. As described previously, 1 the losartan intervention for endpoint reduction life study was designed in the early 1990s when 1 reduction of cardiovascular cv morbidity and mortality with. The losartan intervention for endpoint reduction in hypertension life study reported that a losartan. It was aimed to evaluate the effect of the angiotensin receptor blocker losartan in patients with diabetic nephropathy.
390 320 1664 1268 587 1643 433 1192 5 1510 411 135 18 1285 735 792 418 261 866 17 133 833 319 1449 813 1047 636 1169 423 953 1295 1608 1388 1338 258 608 1209 49 216